ID   TS9;22
AC   CVCL_A691
SY   TS9:22; TS9-22; TS 9:22
DR   cancercelllines; CVCL_A691
DR   CGH-DB; 9347-4
DR   Cosmic; 996326
DR   Cosmic; 998758
DR   Cosmic; 1012126
DR   Cosmic; 1037678
DR   Cosmic; 2089678
DR   Wikidata; Q54973096
RX   CelloPub=CLPUB00588;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=7808006;
RX   PubMed=10071072;
RX   PubMed=10576511;
RX   PubMed=10739008;
RX   PubMed=11226526;
RX   PubMed=14504097;
RX   PubMed=16408098;
RX   PubMed=23955599;
RX   PubMed=26700326;
CC   Population: Japanese.
CC   Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (CelloPub=CLPUB00588; PubMed=7808006; PubMed=10071072; PubMed=10576511).
CC   Sequence variation: Mutation; HGNC; 18318; ASXL1; Simple; p.Arg693Ter (c.2077C>T); ClinVar=VCV000620281; Zygosity=Homozygous (PubMed=26700326).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 02-05-24; Version: 18
//
RX   CelloPub=CLPUB00588;
RA   Fujieda H.;
RT   "Characterization of a novel myelo-megakaryoblastic leukemia cell
RT   line, TS9;22.";
RL   Tokyo Ika Daigaku Zasshi 59:201-210(2001).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=7808006;
RA   Ohyashiki K., Ohyashiki J.H., Fujieda H., Shimamoto T., Kawakubo K.,
RA   Nakazawa S., Suzukawa K., Morishita K., Toyama K.;
RT   "EVI1 expression associated with a 3q26 anomaly in a leukemia cell
RT   line derived from the blast crisis of chronic myeloid leukemia.";
RL   Leukemia 8:2169-2173(1994).
//
RX   PubMed=10071072; DOI=10.1016/S0145-2126(98)00171-4;
RA   Drexler H.G., MacLeod R.A.F., Uphoff C.C.;
RT   "Leukemia cell lines: in vitro models for the study of Philadelphia
RT   chromosome-positive leukemia.";
RL   Leuk. Res. 23:207-215(1999).
//
RX   PubMed=10576511; DOI=10.1016/s0145-2126(99)00131-9;
RA   Uphoff C.C., Habig S., Fombonne S., Matsuo Y., Drexler H.G.;
RT   "ABL-BCR expression in BCR-ABL-positive human leukemia cell lines.";
RL   Leuk. Res. 23:1055-1060(1999).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000),255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric
RT   ALL with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=23955599; DOI=10.1038/ng.2731;
RA   Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y.,
RA   Yoshida K.-i., Okuno Y., Bando M., Nakato R., Ishikawa S.,
RA   Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D.,
RA   Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K.,
RA   Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M.,
RA   Nakamaki T., Ishiyama K., Nolte F., Hofmann W.-K., Miyawaki S.,
RA   Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H.,
RA   Haferlach T., Shirahige K., Miyano S., Ogawa S.;
RT   "Recurrent mutations in multiple components of the cohesin complex in
RT   myeloid neoplasms.";
RL   Nat. Genet. 45:1232-1237(2013).
//
RX   PubMed=26700326; DOI=10.1016/j.exphem.2015.11.011;
RA   Inoue D., Matsumoto M., Nagase R., Saika M., Fujino T., Nakayama K.I.,
RA   Kitamura T.;
RT   "Truncation mutants of ASXL1 observed in myeloid malignancies are
RT   expressed at detectable protein levels.";
RL   Exp. Hematol. 44:172-176(2016).
//